Related Experiment Video
Updated: Jul 24, 2025

Generation of Hypoparathyroid Rats via Carbon-Nanoparticle-Assisted Parathyroidectomy
Published on: July 14, 2023
Disparities in Parathyroidectomy: Who Receives Appropriate Treatment for Primary Hyperparathyroidism?
Alaa Sada1, Kristine T Hanson2, Elizabeth B Habermann2
1Department of Surgery, Mayo Clinic, Rochester, Minnesota.
Parathyroidectomy is underperformed in primary hyperparathyroidism (PHPT). Patients with government insurance face longer waits for surgery, highlighting disparities in care access.
Area of Science:
- Endocrinology
- Surgical Oncology
- Health Services Research
Background:
- Primary hyperparathyroidism (PHPT) is a common endocrine disorder often undertreated with parathyroidectomy, despite established benefits.
- Surgical intervention for PHPT is crucial for managing hypercalcemia and its associated complications, yet disparities in access exist.
Purpose of the Study:
- To evaluate disparities in the receipt of parathyroidectomy among patients diagnosed with PHPT.
- To identify potential barriers to surgical care for PHPT, focusing on demographic and insurance-related factors.
Main Methods:
- A retrospective analysis of adult patients diagnosed with PHPT between 2013-2018 within a health system.
- Kaplan-Meier and multivariable Cox proportional hazards analyses were used to assess parathyroidectomy rates and associated factors.
Main Results:
- Of 2409 patients, 50% underwent parathyroidectomy within one year; this rate was higher (54%) among those meeting strong surgical indications.
- Patients with commercial/self-pay/uninsured status and younger age (≤50 years) were more likely to receive parathyroidectomy.
- Patients with Medicaid/Medicare insurance experienced longer median times to surgery and were less likely to undergo the procedure, even with strong indications.
Conclusions:
- Significant disparities in parathyroidectomy for PHPT were observed, particularly linked to insurance type.
- Patients with governmental insurance faced delays and reduced likelihood of surgery, indicating barriers to care access.
- Further investigation into referral and surgical access barriers is needed to ensure equitable treatment for all PHPT patients.
Related Concept Videos
The Parathyroid Glands
Oxyphil cells, whose functions remain elusive, emerge during late puberty, adding a layer of complexity to the parathyroid gland's intricacies. In contrast, principal parathyroid cells undertake a vital role by...
Treatment for Pulmonary Arterial Hypertension: Receptor Tyrosine Kinase Inhibitors and Calcium Channel Blockers
TKIs, such as imatinib (Gleevec), are particularly effective in tackling the growth and mitogenic factors that become upregulated in PAH patients. These factors contribute to the...
Treatment for Pulmonary Arterial Hypertension: Phosphodiesterase Inhibitors
Among the PDE5 inhibitors, sildenafil (Revatio) stands out as a competitive and selective inhibitor. It operates by elevating cellular levels of cGMP and augmenting signaling through the cGMP-PKG pathway, promoting vasodilation. Upon oral...
Hormones and Bone Tissue
Hormones That Influence Osteoblasts and/or Maintain the Matrix
Several hormones are necessary for controlling bone growth and maintaining the bone matrix. The pituitary gland secretes growth hormone (GH), which, as its name implies, controls bone growth. This happens in several ways: first, it triggers chondrocyte...
Peripheral Artery Disease III: Interprofessional Care
Treatment for Pulmonary Arterial Hypertension: Prostacyclin Receptor Agonists
These agonists bind to the IPR receptor situated on the plasma membrane of the pulmonary artery smooth muscle cells. This binding triggers a cascade of reactions known as the GS-AC-cAMP-PKA pathway. This pathway results in the relaxation of smooth muscle...

